PROM1 and pancreatic neoplasm: The MST of pancreatic cancer patients with CD133+ and CD133- was 4.0 and 8.0 months, respectively (Fig. 2A), and patients with BMI-1+ and BMI-1- was 6.0 and 8.0 months, respectively (Fig. 2B).